| Macular edema due to diabetes mellitus
Eylea HD vs Susvimo
Side-by-side clinical, coverage, and cost comparison for macular edema due to diabetes mellitus.Deep comparison between: Eylea Hd vs Susvimo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSusvimo has a higher rate of injection site reactions vs Eylea Hd based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Susvimo but not Eylea Hd, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eylea Hd
Susvimo
At A Glance
Intravitreal injection
Every 8-16 weeks
VEGF-A/PlGF inhibitor
Ocular implant (intravitreal)
Every 24-36 weeks
VEGF-A antagonist
Indications
- Age related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Wet age-related macular degeneration
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
Dosing
Age related macular degeneration, Macular edema due to diabetes mellitus 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 16 weeks (+/- 1 week); extended dosing once every 20 weeks (+/- 1 week) may be considered after 1 year of successful response.
Diabetic Retinopathy 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 doses, then once every 8 to 12 weeks (+/- 1 week).
Retinal Vein Occlusion 8 mg (0.07 mL) intravitreal injection every 4 weeks for 3 to 5 doses, then once every 8 weeks (+/- 1 week).
Wet age-related macular degeneration, Macular edema due to diabetes mellitus 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 24 weeks (approximately 6 months).
Diabetic Retinopathy 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the SUSVIMO ocular implant with refills every 36 weeks (approximately 9 months).
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to aflibercept or any excipient in EYLEA HD
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to ranibizumab products or any excipient in SUSVIMO
Adverse Reactions
Most common (>=3%) Cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment, vitreous floaters
Serious Endophthalmitis, retinal detachments, retinal vasculitis with or without occlusion, increase in intraocular pressure, thromboembolic events
Postmarketing Retinal vasculitis, occlusive retinal vasculitis, scleritis
Most common (>=10%) Conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, vitreous hemorrhage
Serious Endophthalmitis, rhegmatogenous retinal detachment, implant dislocation, septum dislodgement, vitreous hemorrhage, conjunctival erosion or retraction, conjunctival bleb, postoperative decrease in visual acuity
Pharmacology
Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, inhibiting their binding and activation of VEGFR-1 and VEGFR-2, thereby suppressing neovascularization and vascular permeability in the eye.
Ranibizumab is a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to multiple biologically active forms of VEGF-A, blocking interaction with VEGFR1 and VEGFR2 on endothelial cells and thereby inhibiting neovascularization and vascular leakage.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eylea Hd
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Susvimo
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Eylea Hd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Susvimo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Eylea Hd
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Susvimo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Eylea HdView full Eylea Hd profile
SusvimoView full Susvimo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.